Related Experiment Video
Updated: May 19, 2026
09:25
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Lysyl oxidase polymorphisms and susceptibility to osteosarcoma
Yang Liu1, Bitao Lv, Zhimin He
1Department of Spine Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Plos One
|August 23, 2012
Summary
Genetic variations in the Lysyl oxidase (LOX) gene, specifically the -22G/C and 473G/A polymorphisms, are identified as potential new risk factors for osteosarcoma. These findings suggest LOX gene polymorphisms may influence disease development.
Area of Science:
- Genetics
- Molecular Biology
- Oncology
Background:
- Osteosarcoma (OS) is a complex bone cancer with poorly understood genetic underpinnings.
- Lysyl oxidase (LOX) is crucial for bone structural integrity via collagen and elastin cross-linking.
Purpose of the Study:
- To investigate the association between Lysyl oxidase (LOX) gene polymorphisms and osteosarcoma risk.
- To analyze the functional impact of identified LOX polymorphisms on gene expression.
Main Methods:
- Genomic sequencing of LOX gene exons, splice sites, and promoter regions.
- Luciferase reporter assays to assess promoter activity of LOX polymorphisms.
- Case-control study evaluating the association of LOX polymorphisms and haplotypes with osteosarcoma.
Main Results:
- Three novel polymorphisms (-22G/C, 225C/G, 473G/A) were identified in the LOX gene.
- The -22G/C polymorphism significantly decreased LOX promoter activity.
- Increased prevalence of the -22C allele and 473A allele in osteosarcoma patients compared to controls.
- The CCG haplotype was significantly more frequent in osteosarcoma cases.
Conclusions:
- The -22G/C polymorphism may alter LOX gene expression.
- -22G/C and 473G/A polymorphisms in the LOX gene are potential novel risk factors for osteosarcoma.
- Genetic polymorphisms in LOX may represent a new pathway influencing disease risk.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:41Lethal Alleles
Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:33Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
01:05Proteoglycans
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...